Boston Scientific (BSX) Revenue & Earnings 2020-2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Revenue & Profit
Revenue, EBITDA, operating income, net income, EPS, and shares across quarters
TTM Revenue
$20.61B
17.4%
Q. Revenue
$5.20B
TTM EBITDA
$5.19B
25.3%
TTM Op. Income
$3.79B
33.1%
Q. Op. Income
$1.10B
TTM Net Income
$3.56B
75.8%
Q. Net Income
$1.34B
EPS
$0.9
Shares Out.
$1.48B
0.5%
$20.61B in TTM revenue grew 17.4% YoY, reaching $5.20B last quarter. TTM EBITDA of $5.19B and TTM operating income of $3.79B shows growth is flowing through. Net income of $3.56B TTM confirms the company is converting revenue into profit. Revenue is growing at a healthy pace — a signal to hold.
TTM Revenue
Reveals whether the core business is growing or shrinking
Quarterly Revenue
Highlights seasonal patterns and short-term momentum
TTM EBITDA
Shows if underlying operating profitability is improving
Quarterly EBITDA
Tracks near-term operating profitability trends
TTM Operating Income
Smoothed operating profit over the past four quarters
Quarterly Operating Income
Profit from core operations before financing costs
TTM Net Income
The bottom line — is the company making more money?
Quarterly Net Income
Short-term profit after all expenses and taxes
EPS
Earnings per share — profit attributable to each share
Shares Outstanding
Declining means buybacks benefit remaining holders
